Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Surgery Partners, Inc.
SGRY
NASDAQ·Healthcare·Medical - Care Facilities·Mkt cap $2.2B
$17.23
▲ +3.80%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$11.41 - $24.10
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 24.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Integrated multi-specialty surgical platform with 126 facilities across 31 states providing scale and operational efficiency
- Vertical integration of surgical facilities with ancillary services creating synergies, improved patient outcomes, and higher margins
- Diversified surgical specialty portfolio reducing dependence on single procedure types and providing revenue stability
- Established relationships with physicians and payers built through years of operational experience and market presence
Bear Case
2 risks
- Above-average volatility (beta 1.9).
- Significant premium - growth priced in
Growth
Turning profitable
Steady revenue growth (6% YoY)
Value
Significant premium - growth priced in
Momentum
Hot
+36.3% over 3m
Quality
Stable
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying SGRY right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 4, 2026
MAY 5, 2026
Reported EPS of -$0.03 vs -$0.15 consensus (+80.0% surprise). Revenue of $810.9M vs $797.7M expected (+1.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+80.0%
Next: Aug 4, 2026
Revenue trend · last 8Q
—
—
+18%
+8%
+8%
+7%
+2%
+4%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$762.1M
$770.4M
$864.4M
$776.0M
$826.2M
$821.5M
$885.0M
$810.9M
Margins · last 8Q
Gross
—
Operating
—
Profit
-4.4%
Wall Street consensus
5 analysts · 80% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
80%
Hold
20%
Sell
0%
Median Price Target
$16.00
▼ -7.1% vs $17.23
Latest: Jefferies · $17.00 · May 6, 2026
1 analyst covering